
    <html>
    <head>
    <meta charset="UTF-8">
    <title>Research Report</title>
    <style>
    body,div,ul,li,p,h1,h2,h3,h4 { font-family: 'Segoe UI', 'Roboto', sans-serif; }
    .report-box { background: #f7fafd; border-radius: 16px; border: 1px solid #cde3f7; padding: 32px 24px; margin-bottom:24px; }
    h1 { color: #2261a8; }
    h2, h3 { color: #2674c2; margin-top: 1.6em;}
    h4 { color: #195280; margin-bottom: 0.5em;}
    ul { padding-left: 1.2em; }
    li { margin-bottom: 0.5em;}
    table { border-collapse: collapse; margin: 12px 0;}
    table, th, td { border: 1px solid #9ec6e7; }
    th, td { padding: 8px 12px; }
    .section { margin-bottom: 2em; }
    </style>
    </head>
    <body>
    <div class='report-box'>
<h1>Goldman_Sachs_on_India_CRO_and_CDMO_Signs_of_China+1_progressing</h1>
<p><b>Published Date:</b> 2025-06-23</p>
<p><b>Source:</b> Goldman Sachs</p>
<h3>Sector</h3>
<p>Pharmaceuticals - CRO/CDMO</p>
<h3>Period Covered</h3>
<p>Fiscal year 2025-2027 (FY25-FY27E) and June 2025</p>
<h3>Analysts</h3>
<ul><li>Shyam Srinivasan, CFA</li><li>Karan Vora, CFA</li></ul>
<h3>Executive Summary</h3>
<p>The India CRO/CDMO sector shows strong China+1 supply chain diversification momentum, with companies like Syngene, Neuland, and Cohance converting RFQs to contracts. Biologics investments are growing, highlighted by multiple US acquisitions and greenfield projects. Major modalities include ADCs, oligonucleotides, and peptides. The sector is expected to grow over a 3-5 year horizon with multiple companies forecasting mid-to-high teens sales growth and margin expansion.</p>
<h3>Overall Sentiment</h3>
<p>Positive</p>
<h3>Overall Sentiment Triggers</h3>
<ul><li>Multiple leading CRO/CDMO companies reporting low-teens to high-double-digit sales growth guidance</li><li>Investments in biologics with US acquisitions totaling over US$200mn</li><li>Strong EBITDA CAGR projections (e.g., Cohance 84% FY25-27E)</li><li>Multiple firms trading at premiums with Buy ratings and upside 16%-36%</li><li>Sector-wide theme of China+1 supply chain diversification materializing gradually</li></ul>
<h3>Sector Highlights</h3>
<p>India is maintaining a strong share of API exports relative to China, supported by steady CRO/CDMO-related investments. The sector shows increased client interest across global markets and robust adoption of supply chain diversification strategies from big pharma, albeit hesitation among smaller biotechs due to funding. Investments in biologics capabilities and diversification into new modalities like ADCs, peptides, and oligonucleotides are significant sector themes.</p>
<h3>Industry Metrics Tables</h3>
<h4>[Table ID 1] Company Valuation and Growth Metrics - India CRO/CDMO Space</h4>
<div><p>Summary of ratings, upside potential, valuations (P/E, EV/EBITDA), EBITDA CAGR, and CROCI for leading Indian CRO/CDMO companies as of June 20, 2025.</p><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>Company</th>
      <th>Rating</th>
      <th>Upside Potential</th>
      <th>P/E FY27E (x)</th>
      <th>EV/EBITDA FY27E (x)</th>
      <th>EBITDA CAGR (FY25-27E)</th>
      <th>CROCI FY26E</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Piramal Pharma</td>
      <td>Buy</td>
      <td>36%</td>
      <td>34.2x</td>
      <td>12.8x</td>
      <td>25%</td>
      <td>8%</td>
    </tr>
    <tr>
      <td>Cohance</td>
      <td>Buy</td>
      <td>29%</td>
      <td>39.5x</td>
      <td>26.5x</td>
      <td>84%</td>
      <td>20%</td>
    </tr>
    <tr>
      <td>Syngene</td>
      <td>Buy</td>
      <td>27%</td>
      <td>39.6x</td>
      <td>18.0x</td>
      <td>15%</td>
      <td>12%</td>
    </tr>
    <tr>
      <td>Neuland</td>
      <td>Buy</td>
      <td>21%</td>
      <td>30.7x</td>
      <td>20.5x</td>
      <td>50%</td>
      <td>21%</td>
    </tr>
    <tr>
      <td>Aurobindo</td>
      <td>Buy</td>
      <td>16%</td>
      <td>15.6x</td>
      <td>8.3x</td>
      <td>4%</td>
      <td>14%</td>
    </tr>
    <tr>
      <td>Divi's</td>
      <td>Neutral</td>
      <td>-12%</td>
      <td>55.9x</td>
      <td>39.8x</td>
      <td>20%</td>
      <td>23%</td>
    </tr>
    <tr>
      <td>Laurus Labs</td>
      <td>Sell</td>
      <td>-19%</td>
      <td>41.3x</td>
      <td>20.1x</td>
      <td>33%</td>
      <td>14%</td>
    </tr>
  </tbody>
</table></div>
<h4>[Table ID 2] India Pharma Company Key Financials and Valuation Summary</h4>
<div><p>Market cap, current price, target price, upside/downside, forward P/E, EV/EBITDA multiples, CROCI, sales and EBITDA growth, EPS growth, net debt/EBITDA for leading pharma companies.</p><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th>Company</th>
      <th>Mkt Cap ($ mn)</th>
      <th>Rating</th>
      <th>Current Price (INR)</th>
      <th>Target Price (INR)</th>
      <th>Upside %</th>
      <th>P/E FY26E</th>
      <th>P/E FY27E</th>
      <th>P/E FY28E</th>
      <th>EV/EBITDA FY26E</th>
      <th>EV/EBITDA FY27E</th>
      <th>EV/EBITDA FY28E</th>
      <th>CROCI FY27E</th>
      <th>Sales Growth FY26E</th>
      <th>Sales Growth FY27E</th>
      <th>Sales Growth FY28E</th>
      <th>EBITDA Margin FY26E</th>
      <th>EBITDA Margin FY27E</th>
      <th>EBITDA Margin FY28E</th>
      <th>EBITDA Growth FY26E</th>
      <th>EBITDA Growth FY27E</th>
      <th>EBITDA Growth FY28E</th>
      <th>EPS Growth FY26E</th>
      <th>EPS Growth FY27E</th>
      <th>EPS Growth FY28E</th>
      <th>Net Debt/EBITDA FY27E</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Neuland</td>
      <td>1819</td>
      <td>Buy</td>
      <td>12260</td>
      <td>14775</td>
      <td>21</td>
      <td>45.7</td>
      <td>30.8</td>
      <td>22.9</td>
      <td>29.9</td>
      <td>20.6</td>
      <td>15.1</td>
      <td>25</td>
      <td>29</td>
      <td>27</td>
      <td>21</td>
      <td>27.4</td>
      <td>30.9</td>
      <td>33.9</td>
      <td>61</td>
      <td>43</td>
      <td>33</td>
      <td>72</td>
      <td>48</td>
      <td>34</td>
      <td>-0.3</td>
    </tr>
    <tr>
      <td>Syngene</td>
      <td>2995</td>
      <td>Buy</td>
      <td>644</td>
      <td>800</td>
      <td>24</td>
      <td>72.1</td>
      <td>40.3</td>
      <td>32.1</td>
      <td>26.5</td>
      <td>18.3</td>
      <td>15.0</td>
      <td>15</td>
      <td>6</td>
      <td>26</td>
      <td>18</td>
      <td>25.3</td>
      <td>28.8</td>
      <td>29.1</td>
      <td>-6</td>
      <td>43</td>
      <td>19</td>
      <td>-28</td>
      <td>79</td>
      <td>26</td>
      <td>0.0</td>
    </tr>
    <tr>
      <td>Piramal Pharma</td>
      <td>2984</td>
      <td>Buy</td>
      <td>195</td>
      <td>265</td>
      <td>36</td>
      <td>109.8</td>
      <td>34.2</td>
      <td>19.8</td>
      <td>21.6</td>
      <td>12.8</td>
      <td>9.4</td>
      <td>11</td>
      <td>5</td>
      <td>19</td>
      <td>14</td>
      <td>14.6</td>
      <td>20.4</td>
      <td>23.5</td>
      <td>-3</td>
      <td>67</td>
      <td>32</td>
      <td>102</td>
      <td>221</td>
      <td>73</td>
      <td>3.2</td>
    </tr>
    <tr>
      <td>Cohance Lifesciences</td>
      <td>4346</td>
      <td>Buy</td>
      <td>986</td>
      <td>1275</td>
      <td>29</td>
      <td>55.9</td>
      <td>39.5</td>
      <td>30.8</td>
      <td>35.9</td>
      <td>26.5</td>
      <td>20.8</td>
      <td>20</td>
      <td>173</td>
      <td>21</td>
      <td>17</td>
      <td>32.2</td>
      <td>35.6</td>
      <td>38.2</td>
      <td>173</td>
      <td>34</td>
      <td>25</td>
      <td>143</td>
      <td>42</td>
      <td>28</td>
      <td>0.2</td>
    </tr>
    <tr>
      <td>Laurus Labs</td>
      <td>4125</td>
      <td>Sell</td>
      <td>663</td>
      <td>525</td>
      <td>-21</td>
      <td>63.9</td>
      <td>42.1</td>
      <td>31.5</td>
      <td>26.4</td>
      <td>20.5</td>
      <td>16.7</td>
      <td>16</td>
      <td>16</td>
      <td>17</td>
      <td>14</td>
      <td>22.5</td>
      <td>24.9</td>
      <td>26.5</td>
      <td>38</td>
      <td>29</td>
      <td>22</td>
      <td>80</td>
      <td>52</td>
      <td>33</td>
      <td>1.9</td>
    </tr>
  </tbody>
</table></div>
<h3>Charts And Figures</h3>
<ul>
<li><b>[Chart ID 3] Historical US Healthcare Equity Funding 12-Month Rolling Average</b>: Chart showing equity funding for US healthcare via IPOs and follow-ons hovering below historical average in first five months of 2025.</li>
<li><b>[Chart ID 4] India&#x27;s Relative Share of API Exports vs China</b>: Chart demonstrating Indiaâ€™s API export share relative to China has sustained above long-term average for the past three years.</li>
</ul>
<h3>Macro Trends</h3>
<p>Global biotechnology funding remains volatile and subdued compared to historical averages, impacting CRO/CDMO project flow. The drive to diversify from China-based supply chains is a key macro theme influencing Indian CRO/CDMO growth. Cost differentials favor India, especially for biologics conversion costs and capex. Talent outflow and limited domestic innovation are ongoing challenges. Indian players are expanding overseas R&amp;D footprints to access biotech hubs.</p>
<h3>Headwinds Tailwinds</h3>
<b>Headwinds:</b>
<ul><li>Volatile biotech funding environment affecting project flow</li><li>Conservative capacity expansions by management teams</li><li>Talent outflow internationally increasing attrition risk</li><li>Limited domestic innovation and past failures</li><li>Regulatory compliance risks and customer concentration risk</li></ul>
<b>Tailwinds:</b>
<ul><li>China+1 supply chain diversification driving new contracts and RFPs</li><li>Growing investment in biologics and new modalities (ADCs, oligos, peptides)</li><li>Cost competitiveness in manufacturing and capex vs China and West</li><li>Strong client engagements with big pharma and expanding BD teams</li><li>Sector consolidation and large-scale facility commissioning</li></ul>
<h3>Key Statistics</h3>
<ul><li>Cohance Lifesciences forecasts EBITDA CAGR of 84% over FY25-27E</li><li>Syngene guides low teens underlying/core sales growth in FY26</li><li>Piramal Pharma targets to double revenues and triple EBITDA by FY30</li><li>Cohance Lifesciences aspires to triple revenues from US$335mn in FY25 to US$1bn by FY30</li><li>Aragen Life Sciences FY25 revenues of approximately US$220mn with mid-to-high teens growth guidance for FY26</li></ul>
<h3>Company Summaries</h3>
<div style='margin-bottom:18px; padding:12px; background:#f4f9ff; border-radius:10px;'>
<h4 style='margin:0 0 6px 0'>Syngene International <span style='color:green; font-size:0.95em'>(Positive)</span></h4>
<b>Performance:</b> Experienced increased RFQs and conversion to pilot programs amid improving biotech funding. Commissioning of Stelis Unit 3 approved May 2025; Bayview plant ramp-up underway. Focus on capacity expansion and new modality capabilities in mABs, ADCs, Oligos.<br>
<b>Rationale:</b> Leading player benefitting from supply chain diversification theme. Early-stage capacity expansion to capture new contracts.<br>
<b>Triggers:</b> <ul><li>Core sales growing low teens FY26</li><li>EBITDA margins expected mid-20s% in FY26 with upside as plants ramp up</li><li>12-month price target Rs800 with 24% upside from June 2025 levels</li></ul>
<b>Metrics:</b> <pre style='font-size:0.98em;background:#f9f9f9'>Refer to Table 1 and 2</pre>
<b>Outlook/Guidance:</b> Guides underlying sales growth low teens FY26; margins mid-20s% impaired by new assets costs<br>
<span style='color:#257e36'><b>Top Performer</b></span> 
<b>Reference Tables/Charts:</b> 1, 2<br>
<b>Notes:</b> Buy rating with risks from customer concentration and biotech funding volatility.<br>
</div>
<div style='margin-bottom:18px; padding:12px; background:#f4f9ff; border-radius:10px;'>
<h4 style='margin:0 0 6px 0'>Neuland Labs <span style='color:green; font-size:0.95em'>(Positive)</span></h4>
<b>Performance:</b> Focus on human health APIs with strength in peptides and biotechs services. Ongoing capex of US$30mn to expand peptide capacity. Secured new China+1 projects from innovators.<br>
<b>Rationale:</b> Specialist positioned to benefit from biotech and supply chain shifts. Emphasis on flexible biotech clients.<br>
<b>Triggers:</b> <ul><li>50% EBITDA CAGR FY25-27E</li><li>12-month price target Rs14,775 with 21% upside</li></ul>
<b>Metrics:</b> <pre style='font-size:0.98em;background:#f9f9f9'>See Table 1 and 2</pre>
<b>Outlook/Guidance:</b> Confident on FY26/27 growth driven by CMS and GDS segments with specialty products ramping.<br>
<span style='color:#257e36'><b>Top Performer</b></span> 
<b>Reference Tables/Charts:</b> 1, 2<br>
<b>Notes:</b> Buy rating; risks include regulatory compliance and product concentration.<br>
</div>
<div style='margin-bottom:18px; padding:12px; background:#f4f9ff; border-radius:10px;'>
<h4 style='margin:0 0 6px 0'>TheraNym Bio (Aurobindo) <span style='color:green; font-size:0.95em'>(Positive)</span></h4>
<b>Performance:</b> Engaged in long-term bio CMO deal with MSD; capex US$110mn for integrated bio reactors starting validation batches end 2026. Indian cost advantage noted, though talent shortages exist.<br>
<b>Rationale:</b> Strategic biological CMOs investment with anchor pharma contract.<br>
<b>Triggers:</b> <ul><li>Expected US$125-200mn revenues by 2031 from contract</li><li>Buy on Aurobindo with TP Rs1,275</li></ul>
<b>Metrics:</b> <pre style='font-size:0.98em;background:#f9f9f9'>See Table 1 and 2</pre>
<b>Outlook/Guidance:</b> Bio capacity fills over next several years with margin expansion potential.<br>
<span style='color:#257e36'><b>Top Performer</b></span> 
<b>Reference Tables/Charts:</b> 1, 2<br>
<b>Notes:</b> Not standalone rated; coverage through Aurobindo Pharma.<br>
</div>
<div style='margin-bottom:18px; padding:12px; background:#f4f9ff; border-radius:10px;'>
<h4 style='margin:0 0 6px 0'>Piramal Pharma <span style='color:green; font-size:0.95em'>(Positive)</span></h4>
<b>Performance:</b> CDMO business facing FY26 inventory destocking impact, recovery expected in FY27. Plans capacity expansions in ADCs and expects to double CDMO revenues by FY30.<br>
<b>Rationale:</b> Strong operational leverage with CDMO and CHG (hospital generics) businesses expanding.<br>
<b>Triggers:</b> <ul><li>36% upside to 12-month TP Rs265</li><li>Guidance to double revenues and triple EBITDA by FY30</li></ul>
<b>Metrics:</b> <pre style='font-size:0.98em;background:#f9f9f9'>See Table 1 and 2</pre>
<b>Outlook/Guidance:</b> CDMO growth rebounds FY27; CHG to grow with new capacity registration delays of 6-18 months.<br>
<span style='color:#257e36'><b>Top Performer</b></span> 
<b>Reference Tables/Charts:</b> 1, 2<br>
<b>Notes:</b> Buy rating with regulatory and pricing risk noted.<br>
</div>
<div style='margin-bottom:18px; padding:12px; background:#f4f9ff; border-radius:10px;'>
<h4 style='margin:0 0 6px 0'>Cohance Lifesciences <span style='color:green; font-size:0.95em'>(Positive)</span></h4>
<b>Performance:</b> Strong RFQ growth (~2x), investment in ADC and oligos modalities. Targets to grow revenues from US$335mn in FY25 to US$1bn by FY30. Building GMP ADC capabilities in India and US.<br>
<b>Rationale:</b> First mover advantage in CPT payload ADCs with strong pipeline.<br>
<b>Triggers:</b> <ul><li>84% EBITDA CAGR FY25-27E</li><li>29% upside with 12-month TP Rs1,275</li></ul>
<b>Metrics:</b> <pre style='font-size:0.98em;background:#f9f9f9'>See Table 1 and 2</pre>
<b>Outlook/Guidance:</b> Aspires to triple revenues by FY30 via organic and inorganic growth.<br>
<span style='color:#257e36'><b>Top Performer</b></span> 
<b>Reference Tables/Charts:</b> 1, 2<br>
<b>Notes:</b> Buy rating with product and customer concentration risks.<br>
</div>
<div style='margin-bottom:18px; padding:12px; background:#f4f9ff; border-radius:10px;'>
<h4 style='margin:0 0 6px 0'>Laurus Labs <span style='color:red; font-size:0.95em'>(Negative)</span></h4>
<b>Performance:</b> Aggressive capex plans to double gross block over next 5-6 years, with key investments in ADC and gene therapy. Human health and animal health CDMO businesses running, but current capacity utilization is moderate (~40-45%).<br>
<b>Rationale:</b> Chemistry-centric with diversified pharma and crop health segments but challenged by portfolio mix and scale.<br>
<b>Triggers:</b> <ul><li>-19% downside to 12-month TP Rs525</li><li>Sell rating due to valuation discount and lower CDMO scale</li></ul>
<b>Metrics:</b> <pre style='font-size:0.98em;background:#f9f9f9'>See Table 1 and 2</pre>
<b>Outlook/Guidance:</b> Plans large investments but slower ramp-up and exposure to ARV segment risks persist.<br>
<span style='color:#cb2c18'><b>Weak Performer</b></span> 
<b>Reference Tables/Charts:</b> 1, 2<br>
<b>Notes:</b> Sell rating based on valuation and business mix.<br>
</div>
<div style='margin-bottom:18px; padding:12px; background:#f4f9ff; border-radius:10px;'>
<h4 style='margin:0 0 6px 0'>Sai Life Sciences <span style='color:orange; font-size:0.95em'>(Neutral)</span></h4>
<b>Performance:</b> Focused on CRO with global exploratory labs; expanding capacity from 670KL to ~1,070KL with emphasis on oligos, ADCs, and peptides. Long-term growth guidance 15-20% with margin expansion target to 28-30% in 2-3 years.<br>
<b>Rationale:</b> Growing international presence and capacity expansion to capture rising demand in modalities.<br>
<b>Triggers:</b> <ul><li>15-20% long term growth guidance</li><li>EBITDA margin target 28-30% over next 2-3 years</li></ul>
<b>Outlook/Guidance:</b> Balanced growth from CRO and CDMO segments with capacity buildup.<br>
<b>Notes:</b> Not covered by Goldman Sachs.<br>
</div>
<div style='margin-bottom:18px; padding:12px; background:#f4f9ff; border-radius:10px;'>
<h4 style='margin:0 0 6px 0'>OneSource <span style='color:orange; font-size:0.95em'>(Neutral)</span></h4>
<b>Performance:</b> Independent CDMO focusing on biologics and injectables. Planning 5x expansion of cartridge fill-finish capacity to 220 million over 18 months. FY28 revenue guidance US$400mn and EBITDA US$160mn indicating &gt;30% CAGR FY25-28.<br>
<b>Rationale:</b> Well positioned in GLP-1 and drug-device combination markets with significant capacity expansion underway.<br>
<b>Triggers:</b> <ul><li>&gt;30% CAGR revenue growth FY25-28</li><li>~40% steady state EBITDA margin guidance</li></ul>
<b>Outlook/Guidance:</b> Growth expected to start from FY27 with FY26 outlook uncertain.<br>
<b>Notes:</b> Not covered by Goldman Sachs.<br>
</div>
<div style='margin-bottom:18px; padding:12px; background:#f4f9ff; border-radius:10px;'>
<h4 style='margin:0 0 6px 0'>Dishman Carbogen Amcis <span style='color:orange; font-size:0.95em'>(Neutral)</span></h4>
<b>Performance:</b> Full-stack global CDMO with diversified geographic presence. FY25 capacity utilization varies globally; India at 40-45%. Guidance of 12-15% CAGR over 4-5 years; margin improvement to 20% in FY26 and 25% by FY28.<br>
<b>Rationale:</b> Global footprint provides client access though India operations underutilized.<br>
<b>Triggers:</b> <ul><li>12-15% topline CAGR guidance</li><li>Margin expansion to 25% by FY28</li></ul>
<b>Outlook/Guidance:</b> Capex of CHF25mn p.a. and debt reduction of US$10-15mn p.a. expected.<br>
<b>Notes:</b> Not covered by Goldman Sachs.<br>
</div>
<div style='margin-bottom:18px; padding:12px; background:#f4f9ff; border-radius:10px;'>
<h4 style='margin:0 0 6px 0'>Aragen Life Sciences <span style='color:green; font-size:0.95em'>(Positive)</span></h4>
<b>Performance:</b> Second largest Indian CRO with revenues ~US$220mn in FY25 and ~4,000 scientists. Mid-to-high teens CRO growth in FY25. Investing US$40mn in new clinical manufacturing capacity in Bangalore.<br>
<b>Rationale:</b> Strong CRO growth with integrated drug discovery and expanding bio manufacturing footprint.<br>
<b>Triggers:</b> <ul><li>Mid-to-high teens growth guidance FY26</li><li>Margin expansion to ~29-30% from 26.5% in FY25</li></ul>
<b>Outlook/Guidance:</b> FY26 expansion of bio CDMO capacity to enable new services offers.<br>
<span style='color:#257e36'><b>Top Performer</b></span> 
<b>Notes:</b> Not listed, coverage limited.<br>
</div>
<h3>Conclusion</h3>
<p>The India CRO/CDMO sector is on a positive trajectory driven by the China+1 supply chain diversification theme and increasing investments in biologics and novel modalities. Leading firms exhibit strong growth and margin improvement prospects supported by strategic capacity expansions and enhanced client engagement. Risks remain from funding volatility, talent retention, and regulatory compliance, but overall sector outlook is optimistic with select companies rated Buy with significant upside potential.</p>
<h3>Data Sources</h3>
<p>Goldman Sachs Global Investment Research, Company data, Datastream, Pharmacube.</p>
<h3>Sector Specific</h3>
<p>The sector is witnessing rapid biologics CAPEX with Indian companies acquiring and investing in US facilities (e.g., Syngene&#x27;s US$37mn acquisition, Aragen&#x27;s US$40mn greenfield bio facility, Zydus&#x27;s US$125mn acquisition). Investment focus includes ADCs, peptides, oligonucleotides, and bioconjugation capabilities, with capacity expansions involving modular large reactors (e.g., Syngene&#x27;s Stelis Unit 3 and Bayview facilities, Aurobindo&#x27;s bio reactors). India remains cost competitive with the West and China for biologics conversion and capex costs. Response from China includes increased FTE deployment reflecting competitive pricing. Talent outflow and lack of innovation continue as challenges, with industry initiatives aimed at retention and hiring practices.</p>
<h3>Other Remarks</h3>
<p>The sector shows increasing consolidation and M&amp;A interest, with companies developing M&amp;A-based price targets reflecting the sector&#x27;s growing strategic value. Firms are aligning to global quality and compliance standards to capture large pharma and biotech clients shifting sourcing strategies away from China.</p>
</div>
    </body>
    </html>
    